Taser and Walgreen are big market movers
AP - Wed Dec 24, 12:37PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
RIG: 18.77 (-0.37), BRP: 24.01 (+1.15), ADMS: 16.10 (+1.45), TASR: 26.86 (+0.84), WAG: 76.67 (+0.16)
Market News: Adamas Pharmaceuticals, Virgin America, CalAmp
at The Street - Wed Dec 24, 12:21PM CST
The stock markets in the United States continue to advance with that Russell 2000 close to reaching a record level today. Sign up for our free daily newsletter Yesterday, the Dow Jones Industrial Aver...
VA: 41.00 (+5.19), CAMP: 17.74 (-1.98), ADMS: 16.10 (+1.45)
Premarket Gainers / Losers as of 9:10 ET
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 8:12AM CST
NVGS: 20.00 (+2.10), ACHN: 13.06 (+1.22), ADMS: 16.10 (+1.45), DGLY: 15.62 (+0.82)
FDA clears Adamas Alzheimer's drug
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 7:52AM CST
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
PR Newswire - Wed Dec 24, 7:00AM CST
Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
ACT: 254.20 (-1.68), ADMS: 16.10 (+1.45)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)
Adamas Pharmaceuticals wins six additional US patents for amantadine HCl
M2 - Wed Dec 03, 8:26AM CST
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday that it has received six additional patents in the US, bringing the total number of issued patents for amantadine-based controlled-release products to nine, with 12 more applications pending.
ADMS: 16.10 (+1.45)
Adamas Pharmaceuticals Issued Six Additional U.S. Patents
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US 8,895,616; US 8,895,617 and US 8,895,618), bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to nine, with 12 more applications pending. The newly issued patents include both composition of matter claims and claims covering methods for treatment of neurological diseases, including Parkinson's disease, related to the pharmacokinetic profile of amantadine HCl.
ADMS: 16.10 (+1.45)
Adamas Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 11:00AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 26 Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 3:30 PM Eastern Time.
ADMS: 16.10 (+1.45)
Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Wed Nov 05, 3:02PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 7:30 AM Mountain Time.
ADMS: 16.10 (+1.45)
Adamas Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:44PM CST
ADMS: 16.10 (+1.45)
Adamas Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:03PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.36 per share. Adamas ended the current quarter with $137.5 million in cash and cash equivalents, compared to $85.6 million at December 31, 2013.
ADMS: 16.10 (+1.45)
Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients With Parkinson's Disease
GlobeNewswire - Tue Oct 28, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime.
ADMS: 16.10 (+1.45)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CHTP: 6.52 (-0.03), ADMS: 16.10 (+1.45), ACOR: 39.14 (+0.74), BCLI: 3.85 (+0.22), BSX: 13.13 (+0.07), IPXL: 31.32 (+0.26), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), CVTS: (), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), PRTA: 20.14 (+1.41), PRAN: 1.74 (-0.02), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)
OTC Daily Alert Stock Watch - Adamas Pharmaceuticals, Inc., (NASDAQ: ADMS)
WorldStockWire - Sat Oct 18, 11:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ADMS: 16.10 (+1.45)
5 Big-Volume Stocks to Trade for Big Breakouts
at The Street - Thu Oct 02, 8:20AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
MDVN: 99.23 (+1.23), RCAP: 11.23 (+0.26), ADMS: 16.10 (+1.45), TRGP: 104.31 (+1.60), NRG: 27.74 (+0.60)
Adamas Pharmaceuticals Announces Management Changes
GlobeNewswire - Wed Aug 13, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team.
ADMS: 16.10 (+1.45)
Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 16.10 (+1.45), FRX: 99.00 (-0.77)
Adamas Pharmaceuticals receives US Patent No. 8,796,337 for ADS-5102 and amantadine product candidates
M2 - Wed Aug 06, 5:48AM CDT
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of the US Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease" from the US Patent and Trademark Office (USPTO).
ADMS: 16.10 (+1.45)
United States Patent Issued to Adamas Pharmaceuticals
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
ADMS: 16.10 (+1.45)